Core Insights - The company exited 2025 with strong momentum, achieving double-digit growth in both revenue and earnings per share, supported by 13 products delivering double-digit growth and 14 products exceeding $1 billion in annual sales [2][3] Group 1: Growth Drivers - The momentum is driven by six key growth drivers: Repatha, EVENITY, TEZSPIRE, rare disease treatments, innovative oncology, and the biosimilars portfolio [3] - Repatha, EVENITY, and TEZSPIRE each grew over 30% year-over-year in 2025, achieving record sales and representing multibillion-dollar global franchises [3] - These medicines address significant unmet medical needs, with millions of patients yet to be treated, indicating strong growth potential not only for 2026 but for the entire decade [3]

Summary of Amgen's Conference Call Company Overview - **Company**: Amgen - **Event**: 46th Annual TD Cowen Healthcare Conference - **Key Participants**: Justin Claeys (SVP of Finance), Kave Niksefat (SVP of Global Marketing and Access), Casey Capparelli (Head of IR) Core Industry Insights Financial Performance - Amgen exited 2025 with strong momentum, with 13 products delivering double-digit growth and 14 products exceeding $1 billion in annual sales [2][10] - The company reported double-digit growth in both revenue and earnings per share for 2025, supported by six key growth drivers: Repatha, EVENITY, TEZSPIRE, rare disease portfolio, innovative oncology, and biosimilars [2][10] Product Performance - **Repatha, EVENITY, TEZSPIRE**: Each grew over 30% year-over-year in 2025, representing multi-billion dollar global franchises [2] - **Rare Disease Portfolio**: Generated $5 billion in sales for 2025, up 14% year-over-year, driven by new patient reach and geographic expansion [3] - **Uplizna**: Grew 73% in 2025, with expectations for continued growth following recent approvals [3] - **Biosimilars Portfolio**: Generated $3 billion in sales, growing 37% year-over-year, with strong uptake of PAVBLU [4] Pipeline Developments - 2026 is expected to be a disciplined data year with multiple phase 2 and phase 3 programs [5] - **MariTide**: Positioned as a differentiated treatment for obesity and Type 2 diabetes, with a unique dosing schedule [5] - **Olpasiran**: A small interfering RNA medicine targeting Lp(a), with ongoing studies [6] - **Dazodalibep**: Targeting Sjögren's disease, with two phase III studies expected to complete in the second half of 2026 [6] Market Dynamics Competitive Landscape - Increased competition in the cardiometabolic market, with new entrants expected to grow overall market penetration rather than just share [20] - Amgen's Repatha has a competitive edge due to extensive clinical data, including unique primary prevention data [21] Access and Pricing Strategies - Amgen has successfully negotiated access across various therapeutic areas, ensuring affordability and accessibility of its medicines [12] - **AmgenNow**: A direct-to-patient program for Repatha priced at $239 per month, aimed at uninsured or high-deductible patients [17][18] - The average copay for Repatha has decreased to less than $50 a month, with over half of Medicare patients no longer requiring prior authorization [16] Challenges - Otezla faces European generic competition, with sales of $282 million in 2025 and expected erosion in 2026 due to biosimilar competition [9] - The first quarter of the year typically sees lower sales due to seasonal headwinds and inventory build from the previous quarter [8][9] Additional Insights - The company is focusing on expanding its market share in severe asthma with TEZSPIRE, which can be used across different patient phenotypes [22][24] - Uplizna is being utilized across all lines of therapy, with a significant portion of prescriptions coming from bio-naive patients [28] - The European market remains challenging, but there are signs of governments beginning to react positively to drug pricing and access [33] Conclusion Amgen is well-positioned for sustained long-term growth with a diversified portfolio and a robust pipeline. The company is navigating competitive pressures while focusing on access and affordability for its products, particularly in the cardiometabolic and rare disease markets.

Core Insights - Amgen Inc. is recognized as one of the 13 Best NASDAQ Dividend Stocks to buy currently [1] - Barclays initiated coverage of Amgen with an Equal Weight rating and a price target of $185, indicating ongoing uncertainty regarding the Phase 3 MARITIME trial results [2] - Amgen's Q4 2025 earnings report highlighted strong performance, with 14 products achieving over $1 billion in annual sales and double-digit growth in revenue and earnings per share [3] Group 1: Financial Performance - Amgen's portfolio includes 14 blockbuster products, with 13 products showing double-digit growth and 18 achieving record results [3] - Key products such as Repatha, EVENITY, and TEZSPIRE experienced growth exceeding 30% year-over-year, contributing significantly to long-term growth [4] - The rare disease segment generated over $5 billion in revenue, while oncology growth was bolstered by the BiTE platform, particularly IMDELLTRA, which has become a standard treatment for certain lung cancer patients [4] Group 2: Market Position and Outlook - The company operates in the biotechnology sector, focusing on developing treatments for serious diseases with high unmet medical needs [5] - Barclays expressed a more cautious outlook compared to the broader market, although Amgen's strong guidance helps mitigate concerns [2] - The ongoing debate surrounding the MARITIME trial results is expected to persist, impacting investor sentiment [2]

Core Insights - Amgen reported strong financial performance in 2025, with double-digit growth in revenues and earnings per share, entering 2026 with momentum across its portfolio of medicines [2][5]. Financial Performance - For Q4 2025, total revenues increased by 9% to $9.9 billion compared to Q4 2024, with product sales growing by 7% driven by 10% volume growth, partially offset by a 4% decrease in net selling price [5]. - For the full year 2025, total revenues rose by 10% to $36.8 billion compared to 2024, with product sales increasing by 10% due to 13% volume growth, offset by a 3% decline in net selling price [5]. - GAAP earnings per share (EPS) for Q4 increased by 111% from $1.16 to $2.45, and for the full year, GAAP EPS rose by 88% from $7.56 to $14.23 [5]. - Non-GAAP EPS for Q4 remained relatively unchanged at $5.29, while for the full year, it increased by 10% from $19.84 to $21.84 [5]. Product Sales Performance - Eighteen products achieved record sales for the full year, with fourteen products exceeding $1 billion in annual sales and thirteen products delivering at least double-digit sales growth [5]. - Repatha sales increased by 44% year-over-year to $870 million in Q4, driven by 31% volume growth [6]. - EVENITY sales rose by 39% year-over-year to $599 million in Q4, primarily due to volume growth [6]. - Prolia sales decreased by 10% year-over-year to $1.1 billion in Q4, impacted by lower net selling price and decreased volume [6]. Operating Expenses and Margins - Total operating expenses increased by 5% year-over-year for Q4 and by 6% for the full year [18]. - GAAP operating income for Q4 increased from $2.3 billion to $2.7 billion, with GAAP operating margin rising by 2.5 percentage points to 29.0% [5]. - Non-GAAP operating income for the full year increased from $15.0 billion to $16.2 billion, with non-GAAP operating margin decreasing by 0.8 percentage points to 46.1% [5]. Cash Flow and Balance Sheet - The company generated $8.1 billion of free cash flow for the full year 2025, down from $10.4 billion in 2024, primarily due to timing of working capital and higher capital expenditures [23]. - As of December 31, 2025, cash and cash equivalents totaled $9.1 billion, and debt outstanding was $54.6 billion, with a debt leverage ratio of approximately 3.2 times EBITDA [23]. 2026 Guidance - For 2026, the company expects total revenues in the range of $37.0 billion to $38.4 billion, with GAAP EPS projected between $15.45 and $16.94 [27].

Financial Data and Key Metrics Changes - The company reported a 10% revenue growth through the first nine months of the year, with product sales growth at 11% driven by a 14% volume growth [5][6] - In Q3, revenue growth was 12%, also driven by 14% volume growth [6][7] - Non-GAAP research and development expenses increased by 31% year over year in Q3, with a guidance for mid-twenty percentages for the year [8][9] Business Line Data and Key Metrics Changes - Repatha experienced a 30% year-over-year growth in the first nine months, with significant potential for future growth due to low penetration rates in the PCSK9 therapy market [11] - EVENITY also grew by 30% year over year, holding a 60% market share in the U.S. bone builder market [12] - TESSPIRE achieved 50% year-over-year growth, reaching $1 billion in sales in the U.S. [13] - The rare disease portfolio is annualizing at nearly $5 billion, growing 12% year over year, with Aplisna growing 50% year over year [14] - The biosimilar portfolio grew 40% year over year, now annualizing at approximately $3 billion [16] Market Data and Key Metrics Changes - The company noted that over 90% of women at high risk of fractures remain untreated, indicating significant market opportunity for EVENITY [12] - The penetration of PCSK9 therapy remains low, suggesting ample room for growth for Repatha [11] Company Strategy and Development Direction - The company is focused on a volume-driven growth strategy, investing in innovation and science to enable longer, healthier lives [6][8] - The capital allocation strategy prioritizes innovation, with a strong emphasis on research and development [26][27] - The company is actively engaging with the current administration regarding pricing and access policies, aiming to enhance affordability for patients [31][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum of the business and pipeline, highlighting strong debt paydown and ongoing investments in innovation [6][7] - The company anticipates increased competitive intensity in the biosimilar market but expects growth from its six major growth drivers [49][50] - Management remains optimistic about the potential of Meritide and its applications in various therapeutic areas [66][70] Other Important Information - The company has a capital expenditure guide of $2.2 billion to $2.3 billion for the year, focusing on optimizing network capacity [29] - The company is open to business development opportunities, including licensing and acquisitions, particularly in the rare disease space [55][56] Q&A Session Summary Question: How does Amgen view the momentum going into 2026? - Management highlighted strong revenue growth and volume-driven strategies, indicating optimism for continued momentum [5][6] Question: What are the capital allocation priorities? - The company prioritizes innovation, with a significant focus on research and development, while remaining open to external opportunities [26][27] Question: How is Amgen addressing the competitive landscape in biosimilars? - Management acknowledged the expected increase in competitive intensity but emphasized the growth potential from existing products and new launches [49][50] Question: What is the outlook for the rare disease portfolio? - The company expressed satisfaction with its recent acquisitions and is keen on exploring further opportunities in the rare disease market [55][56] Question: How does Amgen plan to navigate pricing and access challenges? - Management is actively engaging with the administration to ensure patient affordability and fair pricing for innovation [31][32]

Financial Data and Key Metrics Changes - Revenues increased by 12% year over year to $9.6 billion, driven by strong performance across key growth drivers [12][20] - Non-GAAP operating margin was reported at 47%, reflecting significant investments across the business [12][15] - Free cash flow generated in the third quarter was $4.2 billion, indicating operational momentum [15] Business Line Data and Key Metrics Changes - Repatha sales reached $794 million, up 40% year over year, now annualizing at approximately $3 billion [20] - EVENITY delivered $541 million in sales, a 36% increase year over year, with U.S. sales growing 44% [23] - The rare disease portfolio grew 13% year over year to $1.4 billion, with Uplizna sales increasing 46% to $155 million [25] - Tezspire sales rose 40% year over year to $377 million, achieving over $1 billion in sales year to date [27] - The oncology portfolio generated $2.3 billion in sales, growing 9% year over year [29] Market Data and Key Metrics Changes - The biosimilar portfolio saw sales increase by 52% year over year to $775 million, now annualizing at $3 billion [30] - Prolia sales increased by 9% year over year to $1.1 billion, although future quarters may see increased competition negatively impacting sales [24] Company Strategy and Development Direction - The company is focused on expanding access to medicines through initiatives like AmgenNow, which offers Repatha at a significantly reduced price [5][23] - Continued investment in manufacturing with over $3 billion planned for the U.S. in 2025, building on over $40 billion invested since 2017 [7][12] - The company aims to drive innovation in areas of high unmet medical need while maintaining rigorous financial discipline [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining long-term growth, supported by a broad base of innovative medicines [4][11] - The company raised its 2025 guidance for total revenues to a range of $35.8 billion to $36.6 billion and non-GAAP earnings per share to between $20.60 and $21.40 [17] - Management highlighted the importance of the VESALIUS-CV study results for Repatha, which demonstrated significant cardiovascular event reduction [61][62] Other Important Information - The company is actively engaging with policymakers to support policies that improve access and protect innovation [10] - The anticipated approval of Uplizna for generalized myasthenia gravis is expected to expand its patient base significantly [36] Q&A Session Summary Question: Confidence in Olpasiran and Business Development Approach - Management expressed strong confidence in Olpasiran's potential, emphasizing its best-in-class properties and the importance of the Ocean A study [46][47] - The return to pre-Horizon debt levels does not significantly impact the company's business development strategy, which remains focused on earlier-stage opportunities [49] Question: 2026 Guidance and R&D Expenses - Management discussed key growth drivers and the focus on maintaining industry-leading margins while investing in R&D [52][53] - R&D expenses are expected to stabilize after a significant increase, with ongoing investments in late-stage programs [54] Question: VESALIUS-CV Results Impact - The VESALIUS-CV results are anticipated to significantly enhance Repatha's market opportunity, with a focus on improving cardiovascular care [59][60] - Management highlighted the importance of these results in promoting Repatha as a solution for primary prevention of cardiovascular events [62][64] Question: New Biosimilar Guidance Impact - The company does not foresee a change in its strategic focus on biosimilars despite new FDA guidance, maintaining confidence in its competitive position [66][67] - Management believes the biosimilar market is performing well and is committed to ensuring continued access to important medicines [69][70]

Core Insights - Amgen reported a strong Q2 2025 with a 9% increase in GAAP revenue to $9.18 billion and a non-GAAP EPS of $6.02, exceeding analyst expectations [1][2][5] - The company emphasized pipeline advancements and product launches as key drivers of growth, despite a decline in free cash flow [1][4][5] Financial Performance - Non-GAAP EPS reached $6.02, a 21% increase from $4.97 in Q2 2024, surpassing the consensus estimate of $5.28 [2][5] - GAAP revenue was $9.18 billion, up 9% year-over-year, compared to $8.4 billion in Q2 2024 [2][5] - Non-GAAP operating margin improved to 48.9%, a 0.7 percentage point increase from the previous year [2][6] - Free cash flow decreased to $1.9 billion from $2.2 billion in Q2 2024, attributed to higher capital spending and tax payment timing [2][5][15] Product Performance - Sales growth varied across product lines, with Repatha and EVENITY increasing over 30%, while Prolia saw a 4% decline [7][8] - Rare disease products UPLIZNA and TAVNEOS experienced significant revenue increases of 91% and 55%, respectively [7][11] - Inflammation products showed mixed results, with TEZSPIRE growing 46% and Enbrel declining 34% [8] - Oncology products like IMDELLTRA reported strong growth, while older drugs faced competitive pressures [12][13] Pipeline and Innovation - Amgen's pipeline includes promising candidates like MariTide for obesity, which showed strong phase 2 data [10][12] - UPLIZNA is under FDA review for generalized myasthenia gravis, with a decision expected by December 14, 2025 [11] - The company is focusing on expanding its biosimilars portfolio, although pricing pressures are increasing [13][16] Strategic Focus - Amgen is committed to expanding its product pipeline and international market presence while investing in advanced manufacturing [4][16] - The company plans to maintain a capital spending target of $2.3 billion and has set a revenue target of $35.0–$36.0 billion for FY2025 [17][18] - Management highlighted the importance of new drug approvals and the impact of biosimilar competition on established products as key areas to monitor [19]

Financial Data and Key Metrics Changes - Revenues grew by 9% year over year, with volume increasing by 13% [4][10] - Non-GAAP operating expenses rose by 8%, with non-GAAP R&D growth of 18% year over year [33] - Free cash flow generated in the second quarter was $1.9 billion, reflecting operational momentum [33] Business Line Data and Key Metrics Changes - General Medicine sales increased, with Repatha delivering $696 million, up 31% year over year [10][11] - EVENITY sales increased by 32% year over year to $518 million, with significant growth in the U.S. and Japan [11][12] - Rare disease portfolio grew by 19% year over year, delivering nearly $1.4 billion in sales [14] - Oncology portfolio generated $2.2 billion in sales, growing 14% year over year [18] - Biosimilars portfolio sales grew by 40% year over year to $661 million [20] Market Data and Key Metrics Changes - The U.S. market saw continued demand growth across cardiology and primary care [11] - Inflammation treatments showed strong adoption, with TestBio sales up 46% year over year [17] - The biosimilars market is evolving, with Amgen's portfolio generating nearly $12 billion in sales since 2018 [20][86] Company Strategy and Development Direction - The company is focused on innovation and expanding its pipeline, particularly in obesity, rare diseases, and oncology [6][8] - AI is seen as a key driver for enhancing innovation across the company [7][34] - The company aims to improve patient access and affordability while maintaining a commitment to innovation [5][46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver innovation and growth in the long term [9][36] - The company anticipates total revenues for 2025 to be in the range of $35 billion to $36 billion [35] - Management acknowledged the need for reform in the U.S. healthcare system to improve medicine affordability [45][46] Other Important Information - The company is investing heavily in its late-stage pipeline, with a focus on Meritide and other key programs [34][36] - Capital expenditures for 2025 are expected to be $2.3 billion to expand network capacity [34] Q&A Session Summary Question: Granularity on Meritide data in Q4 - Management indicated that more data will be shared in due course regarding the phase two type two diabetes study and chronic weight management studies [41][42] Question: Thoughts on drug pricing reforms - Management emphasized the need for reform in the U.S. healthcare system and expressed a willingness to work with the administration to achieve objectives [44][46] Question: Appetite for M&A in rare diseases - Management remains interested in growing the rare disease business both organically and through potential acquisitions [49][50] Question: Design considerations for Meritide CVOT study - Management acknowledged the interest in the recent data from competitors and indicated that they are closely monitoring the situation [65][66] Question: Timeline for filing approval for bimetuzumab - Management has not disclosed the regulatory strategy yet but is excited about the positive results and their implications for patient treatment [70][71] Question: Confidence in the TestBiR COPD program - Management expressed strong confidence in the mechanism and the responder population for the TestBiR program [106][107] Question: Future of obesity treatments - Management is exploring opportunities to augment their offerings in obesity, including the potential for oral small molecules [111]

Financial Data and Key Metrics Changes - In Q2 2025, revenues grew by 9% year over year, reaching $9.2 billion, with volume growth at an impressive 13% [4][10][31] - Non-GAAP operating expenses rose by 8%, with R&D expenses increasing by 18% year over year [32][33] - Free cash flow generated in the second quarter was $1.9 billion, reflecting operational momentum [32] Business Line Data and Key Metrics Changes - General Medicine saw Repatha sales increase by 31% year over year to $696 million, while EVENITY sales grew by 32% to $518 million [10][11][12] - Rare Disease portfolio sales grew by 19% year over year, totaling nearly $1.4 billion, with TEPEZZA growing by 5% [14][15] - Oncology portfolio sales increased by 14% year over year, generating $2.2 billion, driven by the BiTE platform [18][19] Market Data and Key Metrics Changes - The U.S. market showed continued demand growth across cardiology and primary care, with a significant increase in prescriber engagement [11][12] - Biosimilars portfolio sales grew by 40% year over year to $661 million, contributing significantly to top-line growth [20][21] Company Strategy and Development Direction - The company is focused on advancing a world-class pipeline, with significant investments in innovation and AI to enhance productivity [5][33] - There is a strong emphasis on expanding the rare disease portfolio and exploring M&A opportunities in this area [50] - The company aims to maintain rigorous financial discipline while driving innovation in high unmet medical needs [36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential, highlighting the importance of innovation and patient access [5][36] - The company anticipates total revenues for 2025 to be in the range of $35 billion to $36 billion, with non-GAAP earnings per share between $20.2 and $21.3 [34] Other Important Information - The company is actively engaged in discussions with government officials regarding pricing and tariffs, emphasizing the need for more innovation [5][44] - The company plans to return capital to shareholders through competitive dividend payments, which increased by 6% compared to 2024 [33] Q&A Session Summary Question: Granularity of data on Meritide maintenance - Management indicated that more data will be shared in due course regarding the phase two type two diabetes study and chronic weight management studies [40][41] Question: Thoughts on drug pricing reforms - Management acknowledged the need for reform in the U.S. healthcare system and expressed a willingness to work with the administration to achieve objectives [43][45] Question: Appetite for M&A in rare diseases - Management reiterated interest in growing the rare disease business both organically and through potential licensing or acquisition opportunities [48][50] Question: Design considerations for Meritide CVOT study - Management noted that they are closely following the field and will share plans for pivotal studies in diabetes and cardiovascular outcomes in due course [65][66] Question: Confidence in Testspire COPD program - Management expressed strong confidence in the mechanism and profile of Testspire, emphasizing the distinct pathways involved [106][108]

Demographic Trends - The global population is aging rapidly, with life expectancies increasing and birth rates declining, leading to a demographic imbalance in both developed and emerging economies [1] - By 2030, one in six individuals globally will be over 60, and by 2050, this figure is expected to reach 2.1 billion, with 80% residing in low- and middle-income countries [2] Healthcare Market Dynamics - The global geriatric care market was valued at approximately $1.2 trillion in 2025, up from around $1 trillion in 2022, driven by the rising prevalence of chronic conditions among older adults [3] - There is a growing demand for pharmaceuticals, medical devices, home-based care, and digital health solutions tailored for aging populations [3] Company Strategies - Healthcare companies like Boston Scientific, AbbVie, Amgen, and Dexcom are enhancing operational efficiency to expand their presence in the Seniors & Aging Demographics domain [4] - Pharmaceutical companies are focusing on developing treatments for chronic conditions prevalent in older adults, particularly in immunology, oncology, and neurodegenerative diseases [5] Investment Opportunities - The Healthcare Real Estate Investment Trust (Healthcare REIT) sector is gaining attention, with companies like Community Healthcare Trust and CareTrust REIT focusing on specialized healthcare real estate for the aging population [6] - Digital health solutions, AI-driven diagnostics, and home-based monitoring systems are creating new revenue opportunities for healthcare firms [5] Company Highlights - Boston Scientific has developed devices like the WATCHMAN and SYNERGY systems, catering to the needs of elderly patients [8] - AbbVie is expanding its focus on the aging demographic through strategic acquisitions and partnerships, including the acquisition of Aliada Therapeutics for Alzheimer's treatment [10][11] - Amgen is advancing its R&D pipeline with a focus on elderly-targeted medicines, including osteoporosis treatments and obesity drugs [13][14][15] - Dexcom is enhancing its continuous glucose monitoring systems for seniors, including the launch of the Stelo system, which is designed for ease of use [16][17]